The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

NCT06027567 on ClinicalTrials.gov · last registry update 2026-02-27

Finished 28 January 2025, after enrolling 38 people. Primary outcome, as filed: Weight. semaglutide is approved in the US, but not for cancer and hypertension — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Rigmor Højland Jensen
Sponsor type: Other
Enrollment: 38
Started: 2022-09-02
Primary completion: 2025-01-28 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight

Conditions studied

Idiopathic Intracranial Hypertension · Intracranial Pressure · Obesity · Pseudotumor Cerebri Syndrome · Papilledema · Weight Loss

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.